ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced a conference call and live webcast scheduled for August 6, 2024, at 8:30 a.m. EDT. The event will cover the company's second quarter 2024 financial results and provide operational updates. Interested parties can register for the call to receive dial-in details and a unique PIN. A live webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the event.
ADC Therapeutics SA (NYSE: ADCT), un leader globale in fase commerciale nei coniugati farmaco-anticorpo (ADC), ha annunciato una conferenza telefonica e un webcast dal vivo programmati per 6 agosto 2024, alle 8:30 a.m. EDT. L'evento tratterà i risultati finanziari del secondo trimestre 2024 dell'azienda e fornirà aggiornamenti operativi. Le persone interessate possono registrarsi per la chiamata per ricevere i dettagli per il collegamento e un PIN unico. Un webcast dal vivo sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda, con una versione archiviata accessibile per 30 giorni dopo l'evento.
ADC Therapeutics SA (NYSE: ADCT), un líder global en la etapa comercial de los conjugados de anticuerpos (ADC), ha anunciado una conferencia telefónica y una transmisión en vivo programada para el 6 de agosto de 2024, a las 8:30 a.m. EDT. El evento cubrirá los resultados financieros del segundo trimestre de 2024 de la empresa y proporcionará actualizaciones operativas. Las partes interesadas pueden registrarse para la llamada y recibir los detalles de marcación y un PIN único. Se dispondrá de una transmisión en vivo en el sitio web de relaciones con inversores de la empresa, con una versión archivada accesible durante 30 días después del evento.
ADC 테라퓨틱스 SA (NYSE: ADCT)는 항체 약물 접합체(ADC) 분야에서 상업적 단계의 글로벌 선두주자로서 2024년 8월 6일 오전 8시 30분 EDT에 예정된 컨퍼런스 콜 및 실시간 웹캐스트를 발표했습니다. 이번 이벤트에서는 회사의 2024년 2분기 재무 결과를 다루고 운영 업데이트를 제공합니다. 관심이 있는 분들은 전화를 위해 등록하여 전화 접속 정보와 고유 PIN을 받을 수 있습니다. 실시간 웹캐스트는 회사의 투자자 관계 웹사이트에서 이용 가능하며, 이벤트 후 30일 동안 아카이브된 버전도 사용할 수 있습니다.
ADC Therapeutics SA (NYSE: ADCT), un leader mondial de la phase commerciale dans les conjugués d'anticorps (ADC), a annoncé une conférence téléphonique et un webinaire en direct prévus pour le 6 août 2024 à 8h30 EDT. L'événement portera sur les résultats financiers du deuxième trimestre 2024 de l'entreprise et fournira des mises à jour opérationnelles. Les parties intéressées peuvent s'inscrire pour l'appel afin de recevoir les détails pour se connecter et un code PIN unique. Un webinaire en direct sera disponible sur le site web des relations investisseurs de l'entreprise, avec une version archivée accessible pendant 30 jours après l'événement.
ADC Therapeutics SA (NYSE: ADCT), ein global führendes Unternehmen in der kommerziellen Phase von Antikörper-Wirkstoff-Konjugaten (ADCs), hat eine Telefonkonferenz und einen Live-Webcast angekündigt, die für den 6. August 2024 um 8:30 Uhr EDT angesetzt sind. Die Veranstaltung wird die Finanzergebnisse des zweiten Quartals 2024 des Unternehmens behandeln und betriebliche Updates bereitstellen. Interessierte Parteien können sich für den Anruf registrieren, um die Einwahldaten und eine einzigartige PIN zu erhalten. Ein Live-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer archivierten Version, die 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarter 2024 and provide operational updates.
To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit https://www.adctherapeutics.com/ and follow the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the decrease in total operating expenses for 2024, the expected cash runway into mid-2026, the effectiveness of the new commercial go-to-market strategy, competition from new technologies, and the Company’s ability to grow ZYNLONTA® revenue in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; approval by the NMPA of the BLA for ZYNLONTA® in China submitted by Overland ADCT BioPharma and future revenue from the same, our strategic partners’, including Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the timing and future success from the University of Miami’s IITs in FL and MZL; the timing and results of the Company’s or its partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as the Company’s early-stage pipeline research projects, actions by the FDA or foreign regulatory authorities with respect to the Company’s products or product candidates; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Oaktree and Blue Owl facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
FAQ
When will ADC Therapeutics (ADCT) report its Q2 2024 financial results?
How can investors access ADC Therapeutics' Q2 2024 earnings call?
Where can I find the archived webcast of ADC Therapeutics' Q2 2024 earnings call?
